The present invention relates to the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of tauopathies, synucleinopathies, polyglutamine and polyalanine diseases, leukodystrophies, cystic fibrosis, multiple sclerosis, Amyloidosis diseases, inflammation, metabolic disorders, cardio-vascular disorders, osteoporosis, nervous system trauma, neuropsychiatric disorders, (I), or a tautomer thereof and / or a pharmaceutically acceptable salt thereof, in the treatment of diseases associated with the PPP1R15A pathway, selected from the group of ischemia and related to protein misfolding stress and particularly accumulation of misfolded proteins, Or a pharmaceutically acceptable salt thereof.본 발명은 타우병증(tauopathies), 퇴행성신경질환(synucleinopathies), 폴리글루타민 및 폴리알라닌병(polyglutamine and polyalanine diseases), 백질이영양증(leukodystrophies), 낭포성 섬유증(cystic fibrosis), 다발성 경화증(multiple sclerosis), 리소좀 축적 질환(lysosomal storage disorders), 아밀로이드증 질환(amyloidosis diseases), 염증(inflammation), 대사성 질환(metabolic disorders), 심혈관 질환(cardio-vascular disorders), 골다공증(osteoporosis), 신경계 트라우마(nervous system trauma), 허혈증(ischemia)의 그룹에서 선택되는, PPP1R15A 경로와 관계 있으며 단백질 미스폴딩 스트레스 및 특히 미스폴딩된 단백질의 축적과 관계있는 질환을 치료하는데 있어서, 화학식 (I)의 화합물, 또는 이들의 호변이성체 및/또는 약학적으로 허용 가능한 염의 신규한 용도에 관한 것이다:
